2022. A Case Report Overwhelming response to TNF-alfa inhibitor Infliximab “innovator” Vs. Adalimumab “Bio-similar” in a previously therapy naive adult. Indian Journal of Case Reports. 8, 3 (Mar. 2022), 58–61. DOI:https://doi.org/10.32677/ijcr.v8i3.3317.